Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.
- National clinic network expanding with new sites in Sydney and Victoria
- Projected breakeven for standalone clinics within 9-12 months
- Durable PTSD patient outcomes with over 66% no longer meeting diagnosis criteria
- Therapeutic Goods Administration expands therapist eligibility to include nurses and occupational therapists
- Growing third-party funding from private insurers and government bodies
Clinic Expansion and Financial Trajectory
Emyria Limited (ASX:EMD) is steadily building a national footprint for its Empax clinics, specialising in psychedelic-assisted therapy for PTSD and treatment-resistant depression. The company detailed clinic establishment timelines, with Perth, Brisbane, Melbourne, Sydney, and Mornington sites either operational or in setup phases. Each clinic is projected to reach breakeven within 9 to 12 months of opening, supported by a capital-light model and a flexible, scalable contractor workforce.
Perth leads the network with two clinics and a combined 16 beds, while Sydney’s clinic, once fully operational, will add 4 beds and 20 dosing days per week. The Victorian clinic in Mornington and Brisbane clinics contribute to a total bed capacity of 18 across the network. Emyria’s approach emphasises utilising trained therapists and authorised prescribers to optimise clinic utilisation and patient throughput.
Clinical Outcomes and Patient Impact
Real-world data as of December 2025 shows promising durability in patient outcomes. Over 66% of treated PTSD patients no longer meet diagnostic criteria 12 months post-treatment, with approximately 76% experiencing clinically significant improvements. Patients continue to improve beyond the active treatment phase, underscoring the potential long-term benefits of Emyria’s MDMA-assisted therapy programs.
The company’s treatment protocols involve intensive supervised psychotherapy spanning 90 hours, with individual dosing days generating roughly $10,000 in revenue. Total treatment costs per patient are estimated at $33,000 for PTSD and $22,000 for treatment-resistant depression, figures that compare favourably with conventional care costs, which can exceed $60,000 annually.
Regulatory Advances and Workforce Expansion
Regulatory momentum is a key enabler for Emyria’s growth. In May 2026, the Therapeutic Goods Administration (TGA) expanded the pool of eligible therapists for psychedelic-assisted therapy to include nurses and occupational therapists with mental health experience. This change is expected to accelerate recruitment and improve clinic utilisation, particularly in the second half of 2026. The company is also lobbying to include psychologists, further broadening its workforce base.
This regulatory shift complements Emyria’s specialised training programs for psychiatrists and therapists, ensuring a pipeline of skilled practitioners aligned with clinical and safety standards. The expanded therapist eligibility also supports culturally safe care models and enhances patient access across the Empax network.
Funding Landscape and Market Opportunity
Emyria has secured multiple funding streams, including approvals from the Department of Veterans’ Affairs (DVA) and private health insurers such as Medibank. These reimbursements validate the clinical and economic value of psychedelic-assisted therapy and underpin the company’s revenue growth. The company continues to engage with other insurers and workers compensation bodies to broaden funding coverage.
The Australian mental health market presents a significant opportunity. Approximately 1.1 million adults suffer from major depression and 1.5 million from PTSD, representing a substantial addressable patient base. With Australia pioneering regulatory rescheduling for MDMA and psilocybin-assisted therapies, Emyria holds a first-mover advantage in a market poised for expansion.
Strategic Positioning and Future Prospects
Emyria’s integrated model combines clinical service delivery, real-world data collection, and drug development pipelines, positioning it to leverage global research trends in psychedelic therapies. The company’s Empax Global Partnership Program aims to collaborate with international drug sponsors, potentially expanding indications and clinic utilisation through third-party clinical trials.
With a market capitalisation near A$35 million and a cash position of approximately A$9 million as of March 2026, Emyria is navigating its growth phase with a clear focus on execution. Recent achievements include opening new clinics, publishing 12-month patient outcome data, and advancing funding partnerships, all of which reinforce its leadership in this emerging sector.
Bottom Line?
Emyria’s clinic rollout and regulatory gains set a foundation for scaling psychedelic-assisted therapy, but execution risks and market adoption remain key variables.
Questions in the middle?
- How will Emyria sustain clinic utilisation as new sites come online amid evolving reimbursement landscapes?
- What impact will broader therapist eligibility have on treatment quality and patient outcomes?
- Can Emyria’s global partnership program accelerate drug development and diversify revenue beyond clinical services?